DR LOVE: How well has this issue of neoadjuvant therapy in the locally advanced setting been tested in clinical trials to this point?

DR MOK: There have been trials. For the surgically resectable patient, there’s a NATCH study that looked into the neoadjuvant versus adjuvant versus surgery alone. And that showed a potential slight disease-free survival benefit. But on the Stage III data, actually there had not been too much extensive study. I think there are some switch studies that look into that, just reported early on in a couple of ASCOs before. And then there’s no official difference. But as I said, I’m actually taking this approach as a more practical approach rather than as a definitive so-called efficacy or benefit.

First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) for EGFR mutation-positive non-small cell lung cancer (NSCLC)

Osimertinib and treatment options for patients with disease progression on an EGFR TKI

Other targetable mutations in NSCLC: ALK rearrangement; MET exon 14 splice mutation

Application of immune checkpoint inhibitors in NSCLC

Systemic and localized treatment approaches for NSCLC

Small cell lung cancer, mesothelioma and squamous NSCLC